Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High?

Nektar Therapeutics (NKTR) closed the last trading session at $62.57, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 93.86 indicates a 50% upside potential.The average comprises seven short-term price targets ranging from a low of $30.00 to a high of$ 120.00, with a standard deviation of $29.13. While the lowest estimate indicates a decline of 52.1% from the current ...